Abstract:A systematic engineering of Escherichia coli BL21 (DE3) isoprenoid and central carbon pathways, coupled with translational and protein engineering of a sesquiterpene synthase from Nostoc sp. PCC 7120 yielded high‐efficient β‐elemene production. β‐elemene is one of the most commonly used antineoplastic drugs in cancer treatment. As a plant‐derived natural chemical, biologically engineering microorganisms to produce germacrene A to be converted to β‐elemene harbors great expectations since chemical synthesis and plant isolation methods come with their production deficiencies. In this study, we report the design of an Escherichia coli cell factory for the de novo production of germacrene A to be converted to β‐elemene from a simple carbon source. A series of systematic approaches of engineering the isoprenoid and central carbon pathways, translational and protein engineering of the sesquiterpene synthase, and exporter engineering yielded high‐efficient β‐elemene production. Specifically, deleting competing pathways in the central carbon pathway ensured the availability of acetyl‐coA, pyruvate, and glyceraldehyde‐3‐phosphate for the isoprenoid pathways. Adopting lycopene color as a high throughput screening method, an optimized NSY305N was obtained via error‐prone polymerase chain reaction mutagenesis. Further overexpression of key pathway enzymes, exporter genes, and translational engineering produced 1161.09 mg/L of β‐elemene in a shake flask. Finally, we detected the highest reported titer of 3.52 g/L of β‐elemene and 2.13 g/L germacrene A produced by an E. coli cell factory in a 4‐L fed‐batch fermentation. The systematic engineering reported here generally applies to microbial production of a broader range of chemicals. This illustrates that rewiring E. coli central metabolism is viable for producing acetyl‐coA‐derived and pyruvate‐derived molecules cost‐effectively.

Toward Biosynthetic Design and Implementation of Escherichia coli-Derived Paclitaxel and Other Heterologous Polyisoprene Compounds

Enhancing the biosynthesis of taxadien-5α-yl-acetate in Escherichia coli by combinatorial metabolic engineering approaches

Combinatorial Pathway Optimization in Escherichia Coli by Directed Co‐evolution of Rate‐limiting Enzymes and Modular Pathway Engineering

Overcoming heterologous protein interdependency to optimize P450-mediated Taxol precursor synthesis in Escherichia coli

Construction of an Escherichia coli cell factory to synthesize taxadien-5α-ol, the key precursor of anti-cancer drug paclitaxel

Recent progress in therapeutic natural product biosynthesis using Escherichia coli

Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli

Heterologous erythromycin production across strain and plasmid construction

Engineering Escherichia coli BL21 (DE3) for high‐yield production of germacrene A, a precursor of β‐elemene via combinatorial metabolic engineering strategies

A novel step towards the heterologous biosynthesis of paclitaxel: Characterization of T1βOH taxane hydroxylase

Computational redesign of taxane-10β-hydroxylase for de novo biosynthesis of a key paclitaxel intermediate

Expanding the isoprenoid building block repertoire with an IPP methyltransferase from Streptomyces monomycini.

Recent Advances in Metabolic Engineering, Protein Engineering, and Transcriptome-Guided Insights Toward Synthetic Production of Taxol

Heterologous Production of Epothilone C and D in Escherichia coli

Reassembly of the Biosynthetic Gene Cluster Enables High Epothilone Yield in Engineered Schlegelella Brevitalea.

Enhancing Bio-Isoprene Production in Escherichia Coli through a Combinatorial Optimization Approach

Metabolic engineering and synthetic biology for isoprenoid production in Escherichia coli and Saccharomyces cerevisiae

Metabolic engineering and synthetic biology approaches driving isoprenoid production in Escherichia coli

Engineering cyanobacteria as a new platform for producing taxol precursors directly from carbon dioxide

Plants against cancer: towards green Taxol production through pathway discovery and metabolic engineering